Srn-101

Phase 1

NNicholas Butowski

Srn-101 is one of 3 therapeutic programs targeting High Grade Gliomas. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

High Grade GliomasNot yet recruiting

High Grade GliomasPhase 1

Not yet recruiting

Competition

Competitive Landscape

2 competitors in High Grade Gliomas

#DrugCompanyPhaseTrials

Azeliragon

CCantex Pharmaceuticals

Phase 2

1 2

G207

MM.D. Anderson Cancer Center

Phase 2

1 3

Srn-101

NNicholas Butowski

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 1Not yet recruiting

High Grade Gliomas

NCT07826949

Clinical

Trials by Indication[1]

High Grade Gliomas1 trial

A Phase 1 Window-of-Opportunity Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.

Not yet recruiting·NNicholas Butowski·Phase 1·NCT07826949·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Srn-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Srn-101. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Nicholas Butowski company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNicholas Butowski

Srn-101

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

High Grade Gliomas1 trial

References

Drug Info

Quick Facts

Related News